IP10 C8
Alternative Names: IP10-C8Latest Information Update: 12 Aug 2015
Price :
$50 *
At a glance
- Originator IMTM GmbH
- Class Anti-inflammatories; Antipsoriatics; Small molecules
- Mechanism of Action CD13 antigen inhibitors; Dipeptidyl peptidase 4 inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acne; Psoriasis
Most Recent Events
- 12 Aug 2015 No recent reports on development identified - Phase-I for Acne in Germany (Topical)
- 12 Aug 2015 No recent reports on development identified - Phase-II for Psoriasis in Switzerland (Topical)
- 07 Apr 2011 Phase II development in Psoriasis and clinical development in Acne is ongoing